Suchergebnisse - "Kalac, Matko"

PubPharm (32)

1

Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL/MEITL, SPTCL, HSTCL)

enthalten in: Blood | 2024

von Marchi, E. | Craig, J. | Kalac, M.

2

CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma

enthalten in: Cureus | 2023

von D'Ovidio, T. | Ciccolini, K. | Kalac, M. | +2

3

Idiopathic CD4+ T-lymphocytopaenia with FLT1 mutation complicated by progressive multifocal leucoencephalopathy and EBV+ polymorphic lymphoproliferative disorder

enthalten in: BMJ case reports | 2023

von Rippel, N. | Wong, J. | Hussein, S. | +1

4

Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma

enthalten in: Blood advances | 2023

von Kalac, M. | Jain, S. | Tam, C. | +7

5

Acute cardiomyopathy following a single dose of doxorubicin in a patient with adult T-Cell leukemia/lymphoma

enthalten in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | 2021

von Farina, K. | Kalac, M. | Kim, S.

6

N-quinoline-benzenesulfonamide derivatives exert potent anti-lymphoma effect by targeting NF-κB

enthalten in: iScience | 2020

von Kalac, M. | Mangone, M. | Rinderspacher, A. | +7

7

Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL)

enthalten in: Cell death & disease | 2020

von Xu, X. | Kalac, M. | Markson, M. | +10

8

Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma

enthalten in: British journal of haematology | 2018

von Kalac, M. | Lue, J. | Lichtenstein, E. | +9

9

N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation

enthalten in: Europäisches Patentamt | 2018

von LANDRY DONALD W | OCONNOR OWEN | DENG SHI XIAN | +2

10

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma : an international, multicentre, single-arm, phase 1-2 trial

enthalten in: The Lancet. Oncology | 2018

von O'Connor, O. | Lue, J. | Sawas, A. | +19

CommentIn: Lancet Oncol. 2018 Feb;19(2):162-163. - PMID 29276023